ZEUS Scientific Announces FDA Clearance for the ZEUS dIFine® IFA Imaging and Pattern Recognition System BRANCHBURG, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has cleared ZEUS Scientific's dIFine® digital immunofluorescence system* for use with ZEUS' ANA HEp-2...

ZEUS Scientific Acquires Synthetic Peptides from Sheba Medical Center's Tech Transfer Co. BRANCHBURG, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- ZEUS Scientific has obtained exclusive, worldwide rights to the use of these synthetic peptides as targets of disease-specific autoantibodies in...